Baidu
map

Takeda治疗克罗恩氏病和溃疡性结肠炎新药vedolizumab申请FDA审核

2013-07-03 yangtao 生物谷

Takeda制药公司研发的一种治疗炎症性肠炎药物vedolizumab报请FDA审核。这种药物主要治疗克罗恩氏病和溃疡性结肠炎。这种药物最先是由Millennium医疗公司研发的,Takeda公司花费近90亿美元将其收入旗下 详细英文报道: Takeda has taken another big step forward with one of its key late-stage dr

Takeda制药公司研发的一种治疗炎症性肠炎药物vedolizumab报请FDA审核。这种药物主要治疗克罗恩氏病和溃疡性结肠炎。这种药物最先是由Millennium医疗公司研发的,Takeda公司花费近90亿美元将其收入旗下

详细英文报道:

Takeda has taken another big step forward with one of its key late-stage drugs, filing for U.S. approval for vedolizumab as a new treatment for Crohn's disease and ulcerative colitis, the two most common forms of inflammatory bowel disease. The drug originally was plucked out of the inflammatory portfolio of Millennium Pharmaceuticals after the Japanese pharma company bought it for close to $9 billion.

In the spring of 2012 Takeda released two brief statements on vedolizumab (MLN0002), saying the drug produced a statistically significant rate of clinical remission for Crohn's disease and ulcerative colitis. But in the second Phase III CD trial the company had to concede that the drug failed a primary endpoint on enhanced response. No data were discussed.

Nevertheless, Takeda tapped it as one of 6 programs slated for approval in 2014, making it a key player in the big game to come up with fresh products to replace the Actos money being lost to generics.

The antibody is an alpha-4 beta-7 integrin antagonist targeted at leukocytes and designed to shut down an inflammatory process that triggers Crohn's disease and ulcerative colitis. By aiming for the gut while avoiding interfering with the immune system, Takeda believes it has a safer approach to TNF-alpha blockers like Remicade and Humira.

Decision Resources noted last fall that vedolizumab and Stelara were expected to help significantly grow these two blockbuster markets over the next 8 years. "Decision Resources anticipates that both agents will be primarily reserved for the TNF-refractory population, with vedolizumab achieving slightly greater uptake due to its earlier entry to the market and its potentially lower price."

"The disease burden of IBD is quite significant in the United States, especially on the many young adults living with Crohn's disease and ulcerative colitis," said Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda. "This regulatory submission marks a significant step forward for vedolizumab in the U.S., and as a company we are excited about the possibility of providing this community with a new treatment option."

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694937, encodeId=c0c9169493e84, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Apr 01 09:03:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911617, encodeId=7310191161e51, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Oct 25 01:03:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003477, encodeId=8a0f20034e735, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Tue Jul 23 04:03:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455216, encodeId=02d114552162e, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507528, encodeId=fef2150e52877, content=<a href='/topic/show?id=5c491e1055a' target=_blank style='color:#2F92EE;'>#Takeda#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17105, encryptionId=5c491e1055a, topicName=Takeda)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68059907531, createdName=qindq, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2014-04-01 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1694937, encodeId=c0c9169493e84, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Apr 01 09:03:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911617, encodeId=7310191161e51, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Oct 25 01:03:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003477, encodeId=8a0f20034e735, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Tue Jul 23 04:03:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455216, encodeId=02d114552162e, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507528, encodeId=fef2150e52877, content=<a href='/topic/show?id=5c491e1055a' target=_blank style='color:#2F92EE;'>#Takeda#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17105, encryptionId=5c491e1055a, topicName=Takeda)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68059907531, createdName=qindq, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2013-10-25 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1694937, encodeId=c0c9169493e84, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Apr 01 09:03:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911617, encodeId=7310191161e51, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Oct 25 01:03:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003477, encodeId=8a0f20034e735, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Tue Jul 23 04:03:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455216, encodeId=02d114552162e, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507528, encodeId=fef2150e52877, content=<a href='/topic/show?id=5c491e1055a' target=_blank style='color:#2F92EE;'>#Takeda#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17105, encryptionId=5c491e1055a, topicName=Takeda)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68059907531, createdName=qindq, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1694937, encodeId=c0c9169493e84, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Apr 01 09:03:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911617, encodeId=7310191161e51, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Oct 25 01:03:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003477, encodeId=8a0f20034e735, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Tue Jul 23 04:03:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455216, encodeId=02d114552162e, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507528, encodeId=fef2150e52877, content=<a href='/topic/show?id=5c491e1055a' target=_blank style='color:#2F92EE;'>#Takeda#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17105, encryptionId=5c491e1055a, topicName=Takeda)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68059907531, createdName=qindq, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1694937, encodeId=c0c9169493e84, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Tue Apr 01 09:03:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911617, encodeId=7310191161e51, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Oct 25 01:03:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003477, encodeId=8a0f20034e735, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Tue Jul 23 04:03:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455216, encodeId=02d114552162e, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507528, encodeId=fef2150e52877, content=<a href='/topic/show?id=5c491e1055a' target=_blank style='color:#2F92EE;'>#Takeda#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17105, encryptionId=5c491e1055a, topicName=Takeda)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68059907531, createdName=qindq, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2013-07-05 qindq
Baidu
map
Baidu
map
Baidu
map